Between 1% and 10% developed cold sores, pain or infection in the lesion, anemia, immune mediated events (like vasculitis, pneumonia, worsening psoriasis, glomerulonephritis and vitiligo ), dehydration, confusion, anxiety, depression, dizziness, insomnia, ear pain, fast heart beating, deep vein thrombosis, high blood pressure, flushing, shortness of breath when exercising, sore throat, symptoms of the common cold, stomach pain, back pain, groin pain, weight loss, or oozing from the injection site. Pharmacology
Talimogene laherparepvec is taken up by normal cells and cancer cells like the wild type herpes simplex virus, it is cleared in the same way. Mechanism
Talimogene laherparepvec directly destroys the cancer cells it infects, inducing a systemic immune response against the patients cancer.The virus invades both cancerous and healthy cells, but it cannot productively replicate in healthy tissue because it lacks Infected cell protein 34.5 (ICP34.5). When cells are infected with a virus they shut down and die, but ICP34.5 blocks this stress response, allowing the virus to hijack the cells translation machinery to replicate itself. A herpesvirus lacking the gene coding for ICP34.5 cannot replicate in normal tissue. However, in many cancer cells the stress response is already disrupted, so a virus lacking ICP34.5 can still replicate in tumors. After the virus has replicated many times, the cell swells and finally bursts, killing the cell and releasing the copies of the virus, which can then infect nearby cells.While talimogene laherparepvec is using the cells translation machinery to replicate, it also uses it to make the cell create GM-CSF.
BioVex was founded in 1999, based on research by Robert Coffin at University College London, and moved its headquarters to Woburn, Massachusetts in 2005, leaving about half its employees in the UK.The phase II clinical trial in melanoma was published in 2009 and the phase III trial was published in 2013.Talimogene laherparepvec was approved by the U.S. Food and Drug Administration to treat melanoma in October 2015. It was the first approval of an oncolytic virus and the first approval of a gene therapy in the West. It was approved by the European Medicines Agency in December of that year. Society and culture
Economics
Amgen estimated that talimogene laherparepvec would be priced at US$65,000 per patient at the time it was approved. International Press
The Conversation (website)  which has multilingual articles, published in French and Spanish in October 2022 the following article by  Arthur Battistoni  and Françoise Debierre-Grockiego both of the University of Tours 

Immunotherapy a parasite of dogs that helps fight incurable skin cancers

Research
As of 2016, talimogene laherparepvec has been studied in early stage clinical trials in pancreatic cancer, soft-tissue sarcoma, and head and neck squamous-cell carcinoma; it had also been tested in combination with checkpoint inhibitors ipilimumab and pembrolizumab. See also
Virotherapy
Oncolytic adenovirus

Notes
References
External links
"Talimogene laherparepvec". Drug Information Portal. U.S. National Library of Medicine.